Literature DB >> 15307171

Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice.

Peggy L Kendall1, Emily J Woodward, Chrys Hulbert, James W Thomas.   

Abstract

Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of insulin-producing beta cells in the pancreatic islets. Although T1DM is mediated by T lymphocytes, B lymphocytes are essential for insulitis and disease progression in the non-obese diabetic mouse model. We find that B cells invading the pancreas phenotypically resemble B1a B cells in the peritoneal cavity, including the presence of CD5+. To investigate the link between the peritoneal cavity and lymphocytes invading the pancreas, we used intraperitoneal hypotonic lysis to target these cells. B1a cells were eliminated from the peritoneal compartment by this treatment and were quickly replaced by B2 cells. Both B1a and B2 B cells were concordantly redistributed away from insulitis lesions, while pancreatic T cells showed little change. As a consequence of these events, the onset of diabetes was significantly delayed. These findings indicate that simple perturbations of the B cell-enriched peritoneal compartment can affect the disease process in the pancreas even after islet invasion has begun. Copyright 2004 Wiley-VCH Verlag GmbH & Co.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307171     DOI: 10.1002/eji.200324744

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  26 in total

1.  Asbestos activates CH12.LX B-lymphocytes via macrophage signaling.

Authors:  Devon L Rasmussen; Jean C Pfau
Journal:  J Immunotoxicol       Date:  2011-12-01       Impact factor: 3.000

2.  B lymphocytes protect islet β cells in diabetes prone NOD mice treated with imatinib.

Authors:  Christopher S Wilson; Jason M Spaeth; Jay Karp; Blair T Stocks; Emilee M Hoopes; Roland W Stein; Daniel J Moore
Journal:  JCI Insight       Date:  2019-04-09

3.  Enhanced trafficking to the pancreatic lymph nodes and auto-antigen presentation capacity distinguishes peritoneal B lymphocytes in non-obese diabetic mice.

Authors:  C Alam; S Valkonen; S Ohls; K Törnqvist; A Hänninen
Journal:  Diabetologia       Date:  2009-11-22       Impact factor: 10.122

4.  Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene.

Authors:  Peggy L Kendall; Daniel J Moore; Chrys Hulbert; Kristen L Hoek; Wasif N Khan; James W Thomas
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

5.  Innate stimulation of B1a cells enhances the autoreactive IgM repertoire in the NOD mouse: implications for type 1 diabetes.

Authors:  J Côrte-Real; N Duarte; L Tavares; C Penha-Gonçalves
Journal:  Diabetologia       Date:  2012-03-01       Impact factor: 10.122

6.  NFATc2 (NFAT1) assists BCR-mediated anergy in anti-insulin B cells.

Authors:  Rachel H Bonami; William T Wolfle; James W Thomas; Peggy L Kendall
Journal:  Mol Immunol       Date:  2014-02-06       Impact factor: 4.407

7.  Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes.

Authors:  Julien Diana; Yannick Simoni; Laetitia Furio; Lucie Beaudoin; Birgitta Agerberth; Franck Barrat; Agnès Lehuen
Journal:  Nat Med       Date:  2012-12-16       Impact factor: 53.440

8.  In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes.

Authors:  Daniel J Moore; Jozef Zienkiewicz; Peggy L Kendall; Danya Liu; Xueyan Liu; Ruth Ann Veach; Robert D Collins; Jacek Hawiger
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

Review 9.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  B cells in autoimmune diabetes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2005-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.